January 15, 2008
Enbrel Works Fast Against Alzheimer's Disease?

Injected near the spine Enbrel delivers very rapid results.

A drug commonly used to treat arthritis caused a dramatic and rapid improvement in patients with Alzheimer's disease, according to physicians in California. However, scientists and others not involved in the work worry that the report, which was based on trials in a few patients and hasn't been independently confirmed, may offer little more than false hope for Alzheimer's sufferers and their families.

Alzheimer's patients injected with the anti-inflammatory drug etanercept--marketed as Enbrel--showed dramatic improvements in their functioning within minutes, according to Edward Tobinick, director of the Institute for Neurological Research, a private medical facility in Los Angeles where the patients were treated, and an assistant clinical professor of medicine at the University of California, Los Angeles.

"The patients improve literally before your eyes," says Tobinick, who began using etanercept in Alzheimer's patients three years ago. He uses an unconventional method to administer the drug; he injects it near patients' spines.

Will affluent Alzheimer's sufferers seek out doctors capable of delivering this treatment? Will it spread even without big clinical trials to check its effectiveness? Think about it. If you had early stage Alzheimer's would you try something like this? I would.

Suppose this turns out to work really well. If the relief from this treatment is long lasting then the methods under development to detect beta amyloid plaque years before disease diagnosis will end up getting used in routine screenings of people in their 40s and 50s. One way or another early detection will get used to trigger the use of preventive treatments against Alzheimer's once such treatments become available.

Share |      Randall Parker, 2008 January 15 09:32 PM  Brain Alzheimers Disease

rsilvetz said at January 16, 2008 7:42 PM:

Great way to trip brain tumors into growing. We'll see what the prospective trial shows...

Gene Malloy said at January 17, 2008 6:49 AM:

Are there medical practitioners in the eastern U.S. using Dr. Tobinick's patented extrathecal perispinal injection for the delivery of Enbrel in the treatment of Alzheimers?

D. Mervyn Pipher said at January 29, 2008 11:14 AM:

Although these studies show improvement in cognition, the general consensus in the scientific community is leaning towards, and rightly so, conducting proper and unbiased studies no matter how intense the effects. The method of administration is unproven and should be scrutinized as well in properly controlled independant studies.

On the flip side of this remains the question. If such drastic effects can be realized by inhibiting the TNFα , one of a few toxic Cytokines over produced upon Glial activation by Aβ and other disease-relevant stressors, then wouldn't a small molecule drug targeting this same AD proinflammatory event find similar success in showing improvement and even rapid improvement? Minozac is such a drug. Discovered at Northwestern University, it is orally bioavailable and crosses the BBB easily. In pre-clinical studies it has shown to suppress Glial activation and so then the toxic Cytokines such as TNFα , Interleukin-1β and S100B.

Once-daily oral administration of a low dose (2.5 mg/kg) for 2 weeks, after start of injury (21 days after the start of Aβ infusion), significantly reduced the overproduction of IL-1β , TNFα and S100B back toward basal.

A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2014744#id2707770

Linda Van Eldik PhD Professor Northwestern University
Department: Cell and Molecular Biology
Linda Van Eldik says it well. "Clearly, there is an unmet need for small molecule, orally active, brain-penetrant, anti-cytokine compounds to test as potential new classes of AD therapeutics." http://www.alzforum.org/new/detail.asp?id=1738#

Minozac it would seem fits the bill nicely. Currently licenced to and in development by Transition Therapeutics trades on Nasdaq TTHI http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=tthi

Ben Slagtman said at April 13, 2008 2:21 AM:

Would the aforementioned provide a glimmer of hope for my wife who is currently in a Nursing home suffering from Alzheimer ?

Is such a treatment available in Australia???

I would very much appreciate your response.

My e-mail addres is as show below.
My postal addres is Ben Slagtman
7/120 Clegg Road
Mount Evelyn ( Victoria)

Kris Cheatum said at May 21, 2008 12:45 PM:

How does one arrange for a consultation on this medication at the Institute for Neurological Research at University of California, LA? Please let me know. Thank you.

J Vaughan said at June 13, 2008 1:49 PM:

Dr Tobinick's web site os www.nrimed.com..Los Angeles CA .. Has been treating patients with Embrek for several years. The publication of a controlled "pilot" study in the Journal of Neuroinflammation 9 January 2008 is the event that has stirred everyones interest. SEE http://www.jneuroinflammation.com/content/5/1/2.... I. Vaughan Sun City AZ

Rick said at May 2, 2013 7:32 AM:

We have worked with our son for ten years after a major TBI. Doctors said he would never have to ability to do anything, and highly possible he would die in a short time. We took him home straight from ICU and started working with him. Since 2003 we have taught him how to eat, he can respond, and we are now trying to teach him how to stand. His name is Dustin Hollis, and he can be found on the internet. Stories have been written about of son, and featured on news cast., (goggle his name). We are considering the treatment offered by Dr Tobinick, but are scared. Does it really work? How our lives would change if it did.

Post a comment
Name (not anon or anonymous):
Email Address:
Remember info?

Go Read More Posts On FuturePundit
Site Traffic Info
The contents of this site are copyright